INOVIO PHARMACEUTICALS, INC. Deferred Tax Liabilities, Gross
INOVIO PHARMACEUTICALS, INC. (INO) had Deferred Tax Liabilities, Gross of $1.37 million as of 2025-12-31, per its 10-K filed 2026-03-12.
Financial Statements › Notes › Income Taxes › Components of Deferred Tax Assets and Liabilities › Deferred Tax Assets, Net
us-gaap:DeferredIncomeTaxLiabilities · last filed 2026-03-12
- 2025-12-31: Deferred Tax Liabilities, Gross $1.37M.
- 2024-12-31: Deferred Tax Liabilities, Gross $1.70M.
- 2023-12-31: Deferred Tax Liabilities, Gross $1.99M.
- 2022-12-31: Deferred Tax Liabilities, Gross $2.35M.
| Period end | Deferred Tax Liabilities, Gross |
|---|---|
| 2025-12-31 | $1.37M 10-K · filed 2026-03-12 |
| 2024-12-31 | $1.70M 10-K · filed 2026-03-12 |
| 2023-12-31 | $1.99M 10-K · filed 2025-03-18 |
| 2022-12-31 | $2.35M 10-K · filed 2024-03-06 |
| 2021-12-31 | $3.00M 10-K · filed 2023-03-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| IMMUNIC, INC. (IMUX) | United States | $0.127B | -1.88 |
| Aardvark Therapeutics, Inc. (AARD) | United States | $0.121B | -1.80 |
| CUMBERLAND PHARMACEUTICALS INC (CPIX) | United States | $0.121B | -8.95 |
| Coya Therapeutics, Inc. (COYA) | United States | $0.121B | -6.35 |
| MEDICINOVA INC (MNOV) | United States | $0.130B | -6.04 |
| NRX Pharmaceuticals, Inc. (NRXP) | United States | $0.131B | -6.31 |
| OnKure Therapeutics, Inc. (OKUR) | United States | $0.119B | -3.13 |
| Unicycive Therapeutics, Inc. (UNCY) | United States | $0.134B | -3.70 |
| TuHURA Biosciences, Inc./NV (HURA) | United States | $0.134B | -4.88 |
| Immuneering Corp (IMRX) | United States | $0.113B | -12.51 |